A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
NCT01334710
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
3
Enrollment
OTHER
Sponsor class
Stopped
safety issue observed on another hepatocellular study using OSI906
Conditions
Liver Cancer
Interventions
DRUG:
Sorafenib and OSI-906
Sponsor
Emory University
Collaborators
[object Object]